Next Treatments
Back to Eczema

tipasertideg

TypePill StageStopped · Phase 2 Why it stoppedCompany decision · Sanofi · Nov 20, 2025“Sponsor decision. Not related to safety concern.” (NCT06058156) Latest updateNov 20, 2025Phase 2 study stopped early

What stands out

  • Protein degrader
Derived from WHO name stem · This is a summary of public records for informational purposes only. It is not medical advice.

History

Earliest recorded event: Feb 23, 2021. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.

  • Nov 20, 2025Trial stopped earlyReason: Sponsor decision. Not related to safety concern. ClinicalTrials.gov NCT06058156
  • Oct 23, 2025Phase 2 main data collected · Trial stopped earlyPhase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis Why it stopped: Sponsor decision. Not related to safety concern. ClinicalTrials.gov NCT06058156
  • Oct 20, 2022Phase 1 trial completedA Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS) ClinicalTrials.gov NCT04772885
  • Feb 23, 2021Phase 1 trial startedA Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS) ClinicalTrials.gov NCT04772885

Sources

Trials